# Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

> **NCT01208064** · PHASE2,PHASE3 · TERMINATED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 102 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** pazopanib hydrochloride
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacogenomic studies
- **OTHER:** pharmacological study
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT01208064
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 102 (ACTUAL)
- **Why stopped:** based on IDMC decision
- **Last updated:** 2018-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01208064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01208064, "Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01208064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*